Quality of life in patients with polyneuropathy associated with different types of monoclonal gammopathy of undetermined significance

  • Milica Opalic
  • Stojan Peric
  • Aleksa Palibrk
  • Ivo Bozovic
  • Bogdan Bjelica
  • Zorica Stevic
  • Ivana BastaEmail author
Original article


Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS-PNP) has a chronic and slowly progressive course but can lead to significant disability and reduced quality of life (QoL). The aim of this study was to analyze QoL in MGUS-PNP patients and to determine its predictors. Our study included 51 patients diagnosed with MGUS-PNP (23.5% with IgM, 66.7% IgG or IgA, 7.8% undetermined paraprotein, 2.0% light chains). QoL was assessed using the SF-36 questionnaire. The Medical Research Council Sum Score (MRC-SS), INCAT disability and sensory scores, ataxia score, Krupp’s Fatigue Severity Scale and Beck’s Depression Inventory were also used. Total SF-36 score was 50.0 ± 21.4 and no difference was observed between IgM and IgG/IgA MGUS-PNP. Physical composite score was worse than mental (44.4 ± 21.4 vs. 54.5 ± 20.9). Following factors showed correlation with SF-36 total score in univariate analysis: INCAT disability score, MRC-SS, INCAT sensory score, level of ataxia, fatigue and depression (p < 0.01). Significant predictors of worse SF-36 total score in our MGUS-PNP patients were depression (β = − 0.46, p < 0.01), fatigue (β = − 0.32, p < 0.01) and INCAT disability score (β = − 0.27, p < 0.01). QoL in MGUS-PNP is equally affected in patients with different types of paraprotein. MGUS-PNP patients with more severe functional disability, fatigue and depression need special attention of clinicians since they could be at higher risk to have worse QoL. This should be taken into account when treating subjects with MGUS-PNP.


Monoclonal gammopathy of undetermined significance Polyneuropathy Disability Quality of life Fatigue Depression 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nobile-Orazio E, Barbieri S, Baldini L et al (1992) Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 85:383–390CrossRefGoogle Scholar
  2. 2.
    Gosselin S, Kyle RA, Dyck PJ (1991) Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 30:54–61CrossRefGoogle Scholar
  3. 3.
    Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement: guideline. Br J Haematol 150:28–38Google Scholar
  4. 4.
    Rajabally YA (2011) Neuropathy and paraproteins: review of a complex association. Eur J Neurol 18:1291–1298CrossRefGoogle Scholar
  5. 5.
    Lozeron P, Adams D (2007) Monoclonal gammopathy and neuropathy. Curr Opin Neurol 20:536–541Google Scholar
  6. 6.
    Dalakas MC (2015) Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta 1852:658–666CrossRefGoogle Scholar
  7. 7.
    Merkies IS, Faber CG (2012) Fatigue in immune-mediated neuropathies. Neuromuscul Disord 22:203–207CrossRefGoogle Scholar
  8. 8.
    Falzone YM, Campagnolo M, Bianco M, Dacci P, Martinelli D, Ruiz M, Bocci S, Cerri F, Quattrini A, Comi G, Benedetti L, Giannini F, Lauria G, Nobile-Orazio E, Briani C, Fazio R, Riva N (2018) Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. J Neurol 265:2927–2933CrossRefGoogle Scholar
  9. 9.
    Delmont E, Hiew FL, Cassereau J, Aube-Nathier AC, Grapperon AM, Attarian S, Rajabally YA (2017) Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study. J Peripher Nerv Syst 22:27–33CrossRefGoogle Scholar
  10. 10.
    Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Socie. J Peripher Nerv Syst 15:185–195CrossRefGoogle Scholar
  11. 11.
    Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14:1103–1109CrossRefGoogle Scholar
  12. 12.
    Breiner A, Barnett C, Bril V (2014) INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 50:164–169CrossRefGoogle Scholar
  13. 13.
    Draak THP, Vanhoutte EK, Van Nes SI, Gorson KC, Van Der Pol WL, Notermans NC et al (2015) Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses. J Peripher Nerv Syst 20:277–288CrossRefGoogle Scholar
  14. 14.
    Nobile-Orazio E, Baldini L, Barbieri S (1998) Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 24:93–97CrossRefGoogle Scholar
  15. 15.
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale.Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRefGoogle Scholar
  16. 16.
    Beck A, Steer R, Carbin M (1988) Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 8:77–100CrossRefGoogle Scholar
  17. 17.
    SF-36 Health Survey (original version) language recalls. http:// Accessed Jan 2017
  18. 18.
    Van Nes SI, Vanhoutte EK, Faber CG, Garssen M, Van Doorn PA, Merkies ISJ (2009) Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst 14:268–278CrossRefGoogle Scholar
  19. 19.
    Steiner N, Schwärzler A, Göbel G, Löscher W, Wanschitz J, Gunsilius E (2017) Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? Oncotarget 8:5081–5091Google Scholar
  20. 20.
    Galassi G, Tondelli M, Ariatti A, Benuzzi F, Nichelli P, Valzania F (2016) Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int J Neurosci 127:439–447CrossRefGoogle Scholar
  21. 21.
    Rosenbaum E, Marks D, Raza S (2017) Diagnosis and management of neuropathies associated with plasma cell dyscrasias. Hematological Oncol 63:1–12Google Scholar
  22. 22.
    Ahlskog MC, Kumar N, Mauermann ML, Klein CJ (2012) IgM-monoclonal gammopathy neuropathy and tremor: a first epidemiologic case control study. Park Relat Disord 18:748–752CrossRefGoogle Scholar
  23. 23.
    Bozovic I, Kacar A, Peric S, Nikolic A, Bjelica B, Cobeljic M, Petrovic M, Stojanov A, Djuric V, Stojanovic M, Djordjevic G, Martic V, Dominovic A, Vukojevic Z, Basta I (2017) Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 264:2481–2486CrossRefGoogle Scholar
  24. 24.
    Pruppers MH, Merkies IS, Notermans NC (2015) recent advances in outcome measures in IgM-anti-MAG+ neuropathies. Wolters Kluwer Heal 28:486–493Google Scholar
  25. 25.
    Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA (1999) Fatigue in immune-mediated polyneuropathies. Neurology 53:1648–1664CrossRefGoogle Scholar
  26. 26.
    Saifee TA, Schwingenschuh P, Reilly MM, Lunn MPT, Katschnig P, Kassavetis P et al (2013) Tremor in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 84:1282–1287CrossRefGoogle Scholar
  27. 27.
    Lou JS, Weiss MD, Carter GT (2010) Assessment and management of fatigue in neuromuscular disease. Am J Hosp Palliat Care 27:145–157CrossRefGoogle Scholar
  28. 28.
    EK Vanhoutte CG Faber IS Merkies PeriNorms study group 2013 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands Neuromuscul Disord 23 924 933Google Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  • Milica Opalic
    • 1
  • Stojan Peric
    • 1
  • Aleksa Palibrk
    • 1
  • Ivo Bozovic
    • 1
  • Bogdan Bjelica
    • 1
  • Zorica Stevic
    • 1
  • Ivana Basta
    • 1
    Email author
  1. 1.Neurology Clinic, Clinical Center of Serbia, School of MedicineUniversity of BelgradeBelgradeSerbia

Personalised recommendations